The Ratings Game: AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 6 August, 2017 by The TZ Newswire Staff

The Ratings Game: AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games

On paper, the newly-approved hepatitis C drug Mavyret is a positive steal.
read more

See also
- Next Article Ceiling in 1065 Park Ave. apartment collapses
- Previous Article The Ratings Game: Viacom shares tank almost 12% after CEO offers soft outlook
Editorial Calender

August 2017

M T W T F S S

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

« Jul Sep »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar